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EVALUATING THE USE OF APACHE II SCORE IN PREDICTING THE 
SEVERITY AND CLINICAL OUTCOMES OF ORGANOPHOSPHOROUS 
POISONING 
AUTHOR: Dr. Vivekanandan A    GUIDE: Prof. S. Rajasekaran M.D. 
ABSTRACT 
OBJECTIVE: 
 This study was done to know the efficacy of APACHE II score in predicting the 
severity and clinical outcomes of organophosphorous poisoning. 
METHODOLOGY: 
Patients admitted to toxicology unit of madras medical college and Rajiv Gandhi 
government general hospital with confirmed history of oraganophosphorous poisoning [OPC] 
are included in the study. Total sample size is 75. The study period is July 2014 – September 
2014. All patients admitted in the toxicology ICU unit with confirmed or documented history 
of OPC poisoning are subjected to investigations and the APACHE II score is calculated with 
worst values obtained within 24 hours of admission 
RESULTS: 
 All the patients are included in the analysis the study result showed that the difference 
in APACHE II score is significant among the survivors and non survivors with p value 
0.0001 (<0.05). 
CONCLUSION: 
APACHE II score is useful in the predicting the clinical outcome in the Acute 
Organophosphorous poisonings in the Intensive care settings. 
KEY WORDS: OPC, Atropine, Pralidoxime, APACHE II. 

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INTRODUCTION 
 
Organic phosphorus compounds (OPC) groups of cholinesterase-
inhibiting insecticides that most commonly produces toxicity in humans. 
In clinical practice all insecticides with a ‘P’ atom in their molecular 
structure that possesses cholinesterase inhibition are considered as OPC’s, 
but there are other compounds also possessing the P atom in their 
molecule that also have property of cholinesterase inhibition (e.g.: 
phosphoric acids and phosphonates). Some contain thioesters 
(e.g.:parathion), others are vinyl esters. All those that have property of 
cholinesterase-inhibition (anticholinesterases) that contain phosphorus 
atom in their molecule will be collectively called as OPC’s 
OPC’s act by inhibiting the enzyme acetylcholinesterase thereby 
increasing the acetylcholine levels in the nicotinic and muscarinic 
receptors. This increased Ach will produce the features of cholinergic 
excess syndrome1. 
The most common mode of death in OPC poisoning is respiratory 
failure. Most common OPC poisonings are suicidal especially in rural 
Indian populations. Its high mortality and easy availability for the people 
involved in agriculture related work which makes it ideal suicidal agent 
for people living in rural India. 


Most of the OPC poisoned patients are managed in ICU settings. 
And the new advanced treatment modalities have resulted in increased 
survival in these patients. Such measures are also prolong the in-hospital 
stay and increases the hospital expenses. So there is a need of scoring 
system for prognostication of these patients and also for avoiding 
expensive procedures and treatments. 
The Acute Physiology and Chronic Health Evaluation (APACHE) 
Score2 is the most widely used scoring system in ICU setting. It has 12 
variables and each variable’s score ranges from 0-4. It includes the acute 
physiology score which represents the severity of present illness, the 
Glasgow coma scale and the chronic health status of the patients. The 
maximum score is 71. The score must be calculated using the worst 
clinical parameters obtained in the first 24 hours of ICU admission. The 
APACHE-II score has good discriminatory, reliability and calibration 
compared to other scores in many range of disease process3. 
The need of the study is based on the convergence of the following 
factors 
1. To identify predictors of mortality in OPC poisoned patients 
2. To evaluate the performance of APACHE II scoring systems 
for predicting severity and the outcome of patients poisoned 
with OPC who were admitted to the ICU

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AIMS AND OBJECTIVES 
 
 This study was done to know the use of APACHE II score in 
predicting the severity and clinical outcome of organophosphorous 
poisoning. 
  


REVIEW OF LITERATURE 
Globally anti-cholinesterase insecticide kill many people than any 
other xeno-biotic. Estimates show about 200,000 die in rural Asia. Where 
intentional self-harm is very common and highly toxic OPC insecticides 
are widely used in agriculture. About 3000 to 6000 ventilators are 
constantly needed in Asia alone to provide adequate mechanical 
ventilation to OPC poisoned patients4. 
HISTORY: 
 Clermont in 1854 synthesized the first potent synthetic organo 
phosphorus anticholinesterase tetra-ethyl-pyrophosphate [TEPP], 
Clermont’s report also describes the taste of the compound, and few drops 
of the compound proves rapidly fatal and considered as a remarkable 
achievement5.
Lange and Krueger’s report of blurring and choking followed the 
exposure to dimethyl and diethy-lphospho-flurides in 1932 inspired the 
Schrader and company to investigate and produce number of compounds 
that are used in chemical warfare. At the same time the scientists from 
Great Britain and other allied nations are also motivated and they 
produced the highly fatal compounds like di-isopropyl-phospho-
fluoridate.There are about 50,000 compounds are derived after that and 
screened for pesticide activity. 


EPIDEMIOLOGY: 
OPCs are used in agriculture as an insecticide for the past 50years. 
Its use has declined in past 10-20 years. The reason for decline in use is 
partly due to carbamate group of insecticides, which has similar toxicity 
profile6  
In united states there is about 890 active molecules and marketed as 
20,700 different products. In India, the insecticide industry is fragmented, 
with about 30 -40 large manufacturers and about 400 product 
formulations7. 
The case fatality rate is determined by the local availability of the 
OPCs and the pre-hospital & hospital health care facilities available. Most 
patients consuming the highly toxic OPCs will die before reaching the 
hospital especially in developing countries like India. Hence the hospital 
based mortalities may be falsely low compared to actual mortality. Modes 
by which the people exposed to OPCs other than intentional self-
harm/suicide are 
1. All people are invariably exposed to OPC, through contamination 
of environment and/or occupational use. 
2. Spraying and fogging of insecticides using the applicator causes 
exposures and poisoning to residents and children living in those 
areas. 


3. Occupational dermal exposures to persons working as 
farmers/industrial labours 
4. Food poisoning due contaminated crops 
WHO HAZARD SCALE OF OPCs
8
: 
 OPCs and other anti-cholinesterases are grouped into five classes 
depending upon their toxicity profiles. These estimation was based on 
rat’s oral LD50[median lethal dose in 50% test subjects]. 
 
Sl.no class Hazard type LD50 for the rat 
(mg/kg body weight) 
Oral  Dermal  
1 Class Ia extremely hazardous <5 <50 
2 Class Ib highly hazardous 5-50 50-200 
3 Class II moderately hazardous 50-2000 200-2000 
4 Class III slightly hazardous >2000 >2000 
5 Class IV unlikely to cause 
harm in normal doses 
5000 or higher 


Class Ia 
Extremely hazardous 
Class Ib 
Highly hazardous 
Class II 
Moderately 
hazardous 
Class III 
Slightly hazardous 
Class IV 
Harm unlikely in normal doses 
1. Methyl parathion 
2. Phosphamidon 
3. Phorate 
 
1. Monocrotophos 
2. Triazophos 
3. Oxydemeton-
methyl 
4. dichlorvos 
1. dimethoate 
2. quinalphos 
3. chlorpyriphos 
4. prophenophos 
5. fenthion 
6. ethion 
7. phenthoate 
1. malathion 
2. temephos 
Not associated with clinically 
significant poisonings 
 



     
Commonly available OPCs in india 
1. Monocrotophos is commonly available 36% soluble liquid 
2. Methyl- parathion is commonly available as 2% dust 
  


 
Commonly available OPCs in India 
Chlorpyriphos, malathion and triazophos all available as emulsifiable concentrate and can be used as sprays 
 


PHARMACOLOGY OF OPCs: 
 Organophosphates like any other anti-cholinesterase acts by 
inhibiting the enzyme acetylcholinesterase at the nicotinic and muscarinic 
receptors and rises the level of acetylcholine at the receptor level and 
producing the syndrome of cholinergic excess. 
 
 
 
This figure shows the general structure of OPCs. ‘X’ is the leaving 
group and the ‘R’ may be aliphatic or aromatic ring. 
 
 

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The leaving group determines the nature and many chemical 
characteristics of OPCs and provides the way for classifying into four 
groups 
1. Group1 or phosphoryl-chlorines have quaternary nitrogen in 
X position are powerful anticholinesterases and directly 
stimulate Ach receptors because of similarity to 
acetylcholine in structure. They are used as weapons of war 
2. Group 2 are fluorophosphates with fluorine in X position. 
They are highly volatile and highly toxic. They also used for 
chemical warfare. 
3. Group 3 is cyanophosphates or halo-phosphates other than 
fluorine 
4. Group 4 is major group and comprises the majority of 
presently available OPCs. The configuration of R1 & R2 
defines the characteristics and subgroup. They either belong 
to di-methoxy or di-ethoxy compounds. 
 
 
 
 
  

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Group 1: phosphorylcholines 
Leaving group: substituted quaternary nitrogen 
Echothiophate iodide 
Group 2: fluorophosphates 
Leaving group: fluoride 
Dimefox, sarin, mipafox 
Group 3: cyanophosphates & other halophosphates 
Leaving group: CN−, SCN−, OCN−, halogen other than fluoride 
Tabun 
Group 4: multiple constituents 
Leaving group: 
Dimethoxy 
Azinphos-menthyl, bromophos, chlorothion, 
crotoxyphos, dicapthon, dichlorvos, dicrotophos, 
dimethoate, fenthion, malathion, mevinphos, 
parathion-methyl, phosphamidon, temephos, trichlorfon 
Diethoxy: 
Carbophenothion, chlorfenvinphos, chlorpyriphos, 
coumaphos, demeton, diazinon, dioxathion, disulfoton, 
ethion, methosfolan, parathion, phorate, phosfolan, TEPP 
 


Other dialkoxy: 
Isopropyl paraoxon, isopropyl parathion 
Diamino: 
Schradan 
Chlorinated and other substituted dialkoxy: 
Haloxon 
Trithioalkyl: 
Merphos 
Mixed substituent: 
Crufomate, cyanofenphos 
 
 
 
Oxons are ‘directly acting’ they do not need any conversion to 
inhibit the acetylcholinesterase but OPCS (thions) are ‘indirectly acting’ 
[prodrug] need to be converted into active form before inhibiting 
acetylcholinesterase [eg: parathion→paraoxon, malathion→maloxon].  
Desulfuration reaction to form oxon takes place in mucosa of 
intestine and liver9. 
 
 
 

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MECHANISM OF ACTION: 
OPCs bind to the ‘–OH’ group of the active site of the enzyme 
acetylcholinesterase. On binding, the leaving group of the OPC is split of 
by the acetylcholinesterase resulting in a stable but reversible bonding 
between the OPCs and the AChE and thereby effectively inactivating the 
enzyme. 
 The splitting of the choline-enzyme complex occurs in micro-
seconds. The splitting of the OPC-enzyme complex is prolonged. The 
half-life depends upon the nature of the substituted phosphate. The in 
vitro half-life of spontaneous regeneration of enzyme by di-methoxy 
substituted OPC is 0.7-0.86 hour; that of di-ethoxy substituted OPC 
inhibition is 31-57 hours. Hence spontaneous reactivation is faster for di-
methoxy OPCs. 
 
 
 


 
Normal splitting of acetylcholine by the enzyme acetylcholinesterase 
 
 
 


   
Mechanism of inhibition of AChE by an OPC. The X is the leaving 
group. A serine residue at the active site of the AChE gives up a ‘H’ atom 
to combine with the ‘X’(leaving group) while the active site undergoes 
phosphorylation and inhibition. 
 


Oximes, like pralidoxime or obidoxime, speeds up the 
Rate of reactivation markedly10. However, if the phosphorus is remain 
bounded to the AChE for longer time, because of delayed or inadequate 
infusion of oximes, an alkyl group is non-enzymatically lost this process 
is called “Aging.” If the aging once occurred the AChE is no longer 
reactivated using Oximes and again the half-life of reaction depends upon 
the substituted phosphorous. In vitro half-life of human poisonings with 
dimethoxy OPCs is 3.7hrs while that of diethoxy OPCs is 31hrs. 
PHARMACOKINETICS OF OPCs: 
 OPCs are absorbed well through the gastrointestinal tract, lungs, 
mucous membranes and conjunctiva by ingestion, inhalation and topical 
exposures. Absorption through the intact skin is limited but high 
environmental temperatures, abrasions and dermatitis can enhance the 
absorption through the skin. Absorption through skin and lung explains 
the reason for occupational exposures and some chronic cases of OPC 
toxicities. 
 The time for peak serum concentration for very low dose oral 
chlorpyriphos is around 6 hours but some rapidly acting ‘thions’ and 
some fast ‘oxons’ when ingested in large doses can attain the peak very 
fast and these are responsible for acute presentation within minutes in 
some cases. 
	

 Most of the OPCs are lipophilic, after ingestion these OPCs have 
large volume of distribution and rapidly distributes into the adipose tissue 
where they are protected from the metabolism. It accumulates in highest 
concentration in adipose tissues, re-distribution from these stores is 
responsible for detection of OPCs in serum 48hrs after ingestion. 
Lipophilicity is more for fenthion and dichlofenthion and these 
compounds are notorious to cause cholinergic crisis after many days post 
ingestion.  
 The enzyme called serum paraoxanase cleaves oxons in some 
OPCs which may be protective. Knock out mice deficient in the enzyme 
experiences severe toxicities when given OPCs11. Exogenous 
administration of these enzyme also found protective in some animal 
models. Studies have shown the relationship between human serum 
paraoxanase acticvity in acute and chronic OPC poisonings12. 
PATHOPHYSIOLOGY: 
 Acetylcholine is a neurotransmitter is found in 
1. Parasympathetic and sympathetic ganglia 
2. Neuro-muscular junction(NMJ) 
3. Terminals of all post-ganglionic parasympathetic nerves 
4. Post-ganglionic sympathetic fibres to most sweat glands 
5. Some nerve endings within CNS 
 


 
Mechanism at NMJ: 
As the axon terminal is depolarized, ACh containing vesicles fuse with 
the nerve terminal, releasing acetylcholine into the synapse or NMJ. The 
binding of ACh to its receptors leads to activation (G proteins for 
muscarinic receptors and ligand-linked ion channels for the nicotinic 
receptors). Activation alters the flow of K+, Na+ and Ca2+ ionic currents 
on nerve cells, and this alters membrane potential of the postsynaptic 
membrane/muscle end plate, and formation of action potentials. 



 
Normally acetylcholine released into the synaptic cleft is 
immediately metabolised to choline and acetate and the choline undergoes 
re-uptake into presynaptic terminal. Acetylcholinesterase is normally 
found in nervous tissue, skeletal muscle and red blood cell membrane. 
And the RBC AChE activity correlates well with CNS AChE activity. 
 
COFORMULATIONS: 
 People mainly ingest the product formulations of OPCs and not the 
pure compounds. OPCs sold for agricultural purposes typically have 
emulsifiers like xylene or Chlorohexanone1. The composition of these 
emulsifiers for a given formulation varies across companies. These 
xenobiotics also causes toxicity that is different from OPCs. These 
organic solvents causes aspiration pneumonia once the patient loses the 
consciousness and it is difficult to treat. 
 
CLINICAL MANIFESTATIONS: 
The clinical features are due to Ach excess at muscarinic and 
nicotinic receptors 
Features of muscarinic excess 
1. Salivation,  


2. Lacrimation,  
3. Urination,  
4. Defecation,  
5. Gastric  
6. Emesis,  
7. Bronchorrhea, (can mimic acute pulmonary edema15) 
8. Bronchospasm,  
9. Bradycardia 
10. Miosis. 
Nicotinic features, 
1. fasciculations,  
2. muscle weakness  
3. paralysis 
4. death mostly due to respiratory failure 
The symptom onset varies according to nature of the compound, 
route of exposure and degree of exposure. More the rapid onset of 
poisoning more likely the patient die en-route to the hospital. Patients can 
be symptomatic as quick as 5 minutes on consuming the OPCs 
 Oxon OPCs (eg: mevinphos and monocrotophos) doesn’t need to 
be converted to active molecule so the patient may be symptomatic very 
soon. This is also true for some OPCs which are converted to their 
respective oxons soon. 

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 Lipid solubility also affects the time for onset because they 
distribute into fat stores rapidly (eg: fenthion) and redistribute slowly for 
longer time and produce clinical effects for long period of time. For 
fenthion respiratory failure typically occurs after 24 hours of ingestion. 
Dichlofenthion and fenthion can cause cholinergic features for many days 
after ingestion due to redistribution13,14. 
 
CNS manifestation: 
Many patients presents with awake and alert and complaining of  
1. anxiety,  
2. insomnia,  
3. restlessness,  
4. dizziness,  
5. depression,  
6. Blurred vision and many other non-specific symptoms.  
The level of sensorium detoriates rapidly to lethargy, confusion and 
coma. Convulsions can occur but it is mostly due to hypoxia secondary to 
cholinergic syndrome. 
 Muscarinic symptoms though mostly emphasized, they will not be 
initially predominant or clinically dramatic. These parasympathetic 
features may initially counteracted by the excessive stimulation of 

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autonomic activity through stimulation of nicotinic adrenal receptors and 
post ganglionic sympathetic fibers16.  
1. Mydriasis,  
2. urinary retention  
3. Bronchodilation.  
4. White blood cell de-margination and leucocytosis15,17. 
5. Metabolic effects of sympathetic activity causes glycogenolysis and 
hyperglycemia, ketosis and simulating ketoacidosis18,19. 
 Hyperamylasemia also appears in OPC poisoning. In one study 
four out of 47 cases (9%) had hyperamylasemia. Malathion is mostly 
associated with hyperamylasemia 47(63%) out of 75 cases in one study20. 
Studies in Human poisonings shows associated pancreatic edema and 
necrotizing pancreatitis21. 
Excess Acetylcholine stimulate the vascular receptors and can 
cause hypotension. This is mostly seen with less-fat soluble OPCs like 
dimethoate22. And it is not seen with highly fat soluble OPCs like fenthion 
and chlorpyrifos23. It is also less common with other less fat soluble OPCs 
like methamidophos and oxydemeton-methyl. 
Respiratory manifestations include bronchorrhea, bronchospasm, 
neuro-muscular junction failure of diaphragm and the intercostal muscles 
and loss of respiratory of drive. This causes severe hypoxia due to 

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respiratory arrest and causes death of the patient if it occurs before 
reaching the hospital. Atropine therapy reverses the bronchorrhea and 
bronchoconstriction. But it does not reverses the neuro muscular junction 
failure or the loss of central respiratory drive. Patient need to be ventilated 
until the respiratory function improves.  
The formulated OPCs contain hydrocarbons as co formulation and 
this will cause aspiration and will eventually results in pneumonia, 
chemical pneumonitis and acute respiratory distress syndrome. 
Skeletal muscle activity is governed by the acetylcholine through 
the nicotinic receptors. Excess acetylcholine at the nicotinic level will 
produce the features similar to the depolarizing neuro muscular blockade 
(eg: succinylcholine). This produces the muscle weakness and 
fasciculations and this is considered to be pathognomonic of the parathion 
poisoning. Cranial nerve abnormalities are not common during the acute 
presentation. But severe poisonings results in paralysis. Rigidity and 
choreoathetosis which are the features of extrapyramidal system is also 
not seen in acute presentation. But seen in patients recovering from 
cholinergic excess. 
 
 

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DELAYED SYNDROMES: 
  A syndrome of delayed weakness resulting in respiratory muscle 
weakness without fasciculations or cholinergic features it was first 
reported in 197424. This is intermediate syndrome (IMS) defined as 
occurring 24-96 hours after acute OPC poisoning and following 
resolution of the cholinergic features25. Patients typically presents with 
proximal muscle weakness typically of neck flexors and cranial nerve 
palsies, respiratory failure that may last for several weeks. Consciousness 
is not impaired until it is not complicated by pneumonia or hypoxic 
encephalopathy. The first sign of IMS is patient’s inability to lift the head 
from bed. 
  The exact pathophysiology of syndrome is unknown. It’s clearly 
due to the dysfunction of neuro muscular junction with respiratory failure 
resulting from weakness of intercostal muscles and diaphragm. 
Preservation of consciousness suggests that the central respiratory drive is 
less likely to be involved. One more proposed mechanism is down 
regulation of neuro muscular junction synaptic mechanism26. This 
dysfunction is will require time to get repaired. And will persists even 
after the OPCs are removed from the body, and may require long periods 
of assisted ventilation27. 


  Small case series and case reports suggests that the IMS is more 
common in fenthion poisoning than that of Malathion, chlorpyriphos and 
fenitrothion poisoning27. 
 Clinical examination is the most reliable method of diagnosis of 
IMS. Electromyography studies shows the tetanic fade suggestive of both 
pre synaptic and post synaptic involvement. Recent work has suggests 
characteristic electro physiologic features of increment and decrement 
phenomenon that can be identified before neurological and respiratory 
paralysis28.  
 A study showed that intermediate syndrome correlates best with 
acute cholinergic crisis. And it is continuum from the neuromuscular 
junction dysfunction occurring at the time of cholinergic crisis29. Patients 
acutely poisoned with dimethoate shows that patients after recovering 
from acute cholinergic crisis may need ventilator support. But this is short 
lived and the patient will improve from cholinergic crisis and regain 
consciousness and central respiratory drive but patient may still may need 
ventilator support. This matches to the classical description of IMS. But 
studies also showing that patient may need ventilator support before 24 
hours and also after 96 hours. 
 Some authors suggest that IMS may be due to inadequate Oxime 
therapy30. This is suggested by a fact that the patients poisoned with OPCs 


like dimethoate and fenthion have AchEs that are poorly responsive to 
oxime theraphy and hence have higher incidence of IMS. In contrast 
AChE that are inhibited by chlorpyriphos have less incidence of IMS 
when compared to the former. Overall the delayed NMJ dysfunction may 
be either due to ineffective oxime therapy or may be due to ingestion of 
OPCs that are poorly responsive to Oximes. 
 Treatment of intermediate syndrome is mainly supportive. Patient 
needs ventilator support and with nursing care to prevent bedsores and 
ventilator acquired pneumonia. Pralidoxime and atrophine are needed to 
control the cholinergic symptoms that occur in-between. Pralidoxime can 
revert the IMS when given early during its development. But once the 
neuro muscular dysfunction occurs the oximes are unlikely to revert it. 
Most of the IMS patients need ventilator support from 5-18 days31.  
 
OPC INDUCED DELAYED POLYNEUROPATHY:[OPIDN] 
 Peripheral neuropathies can occur days to weeks after acute 
exposure to OPCs and also can chronic exposures to OPCs like in case of 
occupational exposures. OPIDN is due to inhibition of phosphorylation of 
the enzyme called Neuropathy Targeted Esterases [NTE]. {Now known 
as lysophospholipase[lysoPLA]} inside the nervous tissue.  
	

This enzyme catalyses the breakdown of endoplasmic reticulum–
membrane phosphatidylcholine, it is the major phospholipid of eukaryotic 
cell membranes. Neuropathic OPs cause a transient loss of NTE-lysoPLA 
activity, putatively disrupting membrane phospholipid homeostasis, 
axonal transport, and glial–axonal interactions. 
A second mechanism of OPIDN is imbalance in calcium 
homeostasis. This lead to the activation of calcium-activated neutral 
protease and causes increases in calcium/calmodulin-dependent protein 
kinases. These events can contribute to aberrant phosphorylation of 
cytoskeletal proteins and protein digestion occurring in the terminal axon 
that can proceed in same way like Wallerian-type degeneration. Many 
experimental studies showed improvement of the signs and symptoms of 
OPIDN by restoring calcium balance. Other studies have used prior 
administration of NTE inhibitors, such as carbamates, thiocarbamates, 
sulfonyl fluorides and phosphinate to prevent OPIDN32. 


 
 
Panel A: Axonal degeneration and vacuolization of sural nerve fibers in 
patients following an acute OPC [phosphamidon] exposure. 
Panel B: T2 weighted sagittal MRI of spine showing atrophy especially in 
thoracic cord. 



 
OPIDN may result from exposure to OPCs that neither inhibit RBC 
cholinesterase nor produce clinical cholinergic toxicity. The commonly 
implicated chemicals include triaryl phosphates, such as tri-ortho-cresyl 
phosphate (TOCP), & di-alkyl phosphates, such as mipafox, mephosfolan, 
and chlorpyrifos. Pathologic findings demonstrate effects mainly on large 
distal neurons, with axonal degeneration followed by demyelination33. 
Contaminated foods and beverages were responsible for epidemics 
of OPIDP and encephalopathy. In the 1930s, thousands of individuals in 
the United States became weak or paralyzed after drinking a supplement 
containing TOCP—an outbreak named “Ginger Jake paralysis”. 
Contaminated mineral and cooking oils were responsible for outbreaks of 
delayed OPIDP in Vietnam and Sri Lanka.  
Vague distal muscle weakness & pain are the usual presenting 
symptoms and can progress to paralysis. The administration of atropine or 
Oximes did not alter the onset and clinical course of these symptoms. 
Corticospinal tract signs can appear weeks to months after acute 
exposures.  
Electromyographs and nerve conduction studies are helpful in 
diagnosing by identifying the type of neuropathy (such as myelinopathy, 
axonopathy, or transmission neuropathy) and differentiating it from 
similar presentations such as Guillain-Barre syndrome. The recovery of 
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these patients is highly variable, commonly with some residual deficits, 
and occurs over months to years. 
 
CHRONIC TOXICITY OF OPCS: 
 Illness may also result from chronic exposure to excessive amounts 
of OPCs. Chronic exposure most commonly occurs in workers who have 
regular contact with these xenobiotics, but may also occur in individuals 
who have repeated contact with excessive amounts of insecticides in their 
living environments.  
Exposure to cholinergic ophthalmic preparations chronically can 
also result in toxicity34. Although tolerance to acute cholinergic systemic 
effects of OPs (including death in rats) may be seen in long-term 
exposures, persons having the long term exposure to OPCs will show the 
symptoms after substantial length of time. These effects range from some 
nonspecific neurological symptoms and weakness to full blown 
muscarinic symptoms like miosis, diaphoresis, bronchorrhea, diarrhea and 
vomiting35,36,37.  Butrylcholinesterase activity is the most sensitive 
measure of exposure. Persons working in those environments should have 
a baseline BuChE measurements done for monitoring the exposures and 
comparison38,39. 
Parkinson disease was associated with chronic exposure to 
insecticides including OPCs40. Some individuals have a genetic 
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susceptibility. Parkinsonism like movement disorders occur significant 
number of patients with acute OPCs exposure. They are self-limited and 
they resolve over months to years. 
 
BEHAVIORAL TOXICITY: 
Acute or chronic exposure to OPCs also associated with 
behavioural toxicity. Symptoms include confusion, anxiety, psychosis, 
depression, drowsiness, fatigue, and irritability. Electroencephalographic 
changes may be seen and lasts for weeks41. Morphologic changes in the 
basal ganglia of one child identified with single photos emission 
computed tomography scan (SPECT) following poisoning. Studies have 
shown a cognitive processing deficit after acute OPCs self-poisoning 
lasting for at least six months and this is not found in matched populations 
who had poisoned themselves with Acetaminophen42,43. So far there is no 
clear evidence for neuro-psychiatric deficiencies resulting from 
subclinical exposure to OPCs. 
 
DIAGNOSTIC TESTING: 
With a history of acute exposure to OPCs and the patient presenting 
in acute cholinergic crisis the diagnosis of OPC poisoning is straight 
forward. 
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Although many authors list a range of clinical signs for the cholinergic 
crisis (SLUDGE, DUMBELS), most patients with significant amount of 
poisoning can be identified by the presence of excessive sweating, pin 
point pupil and difficulty in breathing. When the history is unreliable the 
diagnosis must be confirmed by other means. Treatment of patient with 
acute cholinergic syndrome should not delayed for confirmation of 
diagnosis. 
Most appropriate method of identifying the cholinesterase 
inhibition is finding the OPCs in biologic tissues or measuring the serum 
cholinesterase activity. Although the metabolites of the OPCs are 
available in the urine and serum they are rarely measured46,47,48, and if so 
it takes hours to get results and the normal limits of these compounds are 
not established in epidemiological grounds. Moreover “normal” ranges 
and toxic concentrations are not established for most. Therefore at 
present, verifying OPC poisoning relies on measurement of plasma 
cholinesterase activity. 
CHOLINESTERASE ACTIVITY: 
The commonly measured cholinesterases are the 
butyrylcholinesterase and the Red cell cholinesterase. The 
Butyrylcholinesterase is synthesised in the liver and then it is secreted 
into the plasma where it will metabolize the xenobiotic like scoline and 
cocaine. The red cell acetylcholinesterase and neuronal 
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acetylcholinestearses are both product of the same gene, but the 
difference in mechanism is due to the mechanism of membrane 
attachement. The red cell acetylcholinesterase is a [GPI]glycosyl-
phosphatidyl-iositol anchor linked to the red cell. Whereas the neuronal 
AChE is secreted in the form of tetramers or dimers and they are attached 
to post-synaptic membrane through other proteins.
 The inhibition of red cell AChE and BuChE is the only markers of 
enzyme inhibition by OPCs. Their inhibition is not actually the cause for 
symptoms or they do not produce the symptoms per se. but the red cell 
acetylcholinesterase activity is accurately correlating with neuronal AChE 
activity in OPC poisoning49. 
 There is lot of inter-individual and inter-chemical variations in the 
degree and the duration with which the OPCs affect the particular 
cholinesterases. After a significant exposure first to fall is the 
butyrylcholinesterase activity followed by the red cell 
acetylcholinesterase activity. At the time when the patients presents to the 
hospital both cholinesterase activity fall markedly below the baseline 
values though the sequence of fall may vary15.the red cell 
acetylcholinesterase and butyrylcholinesterase levels vary among species 
to species and it will further complicate the animal studies. Human 
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plasma actually has very low AChE and hence papers mentioning the 
human plasma acetylcholinesterase activity actually means BuChE. 
BUTYRYLCHOLINESTERASE:  
 
Butyrylcholinesterase activity usually returns before the red cell 
acetylcholinesterase activity with mild exposures and no further exposure 
to the same inciting OPCs. But the BuChE activity is less sensitive than 
the RBC-AChE. Low butyrylcholinesterase activity is seen in patients 
with lot of co-morbid conditions50 like  
• iron deficiency anemia 
• hepatic parenchymal disease 
• malnutrition 
• chronic debilitating illness 
• congenital absence of the enzyme 
• genetic defects 
Wide ranges of normal activity make the patient to suffer a drastic 
fall in BuChE activity but the lab value in essentially in normal range. As 
high as 20% day to day variation in normal activity is seen with healthy 
subjects. An admission butyrylcholinesterase activity is little value in 
patients because it varies among the ingested OPCs and does not cause 
any clinical effects, but it can be used if the ingested OPCs is known and 
the clinical effect is specifically studied with that OPCs. 
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RED CELL ACETYLCHOLINESTERASE [RBC-AChE]: 
 Acetylcholinesterase in the RBC is true acetylcholinesterase and it 
correlates well with the neuronal acetylcholinesterase. As per some 
authors if RBC-AChE falls below 50%, clinical OPC poisoning 
occurs15.and if falls below 30% NMJ dysfunction occurs49.  Haemoglobin 
concentration can be related well with RBC-AChE Reducing the 
variations with varying haematocrit51. 
• Mean range in many people is 600-700mU/µmol Hb 
• In one study Caucasian populations had 651±18 mU/µmol 
Hb. 
All RBCs exposed to OPC must be replaced. RBC-AChE takes 
longer time to recover after OPC exposure, it takes about 66 days for the 
RBC-AChE to recover. Animal studies shows that neuronal 
acetylcholinesterase activity may return to normal more rapidly than 
RBC-AChE. Red blood cell cholinesterase activity may be low but the 
patients may show no cholinergic features and have normal neuronal 
acetylcholinesterase and normal NMJ action. This is the demerit of 
measuring the RBC-AChE in case of sub-acute OPC poisoning as we 
cannot predict exact time or duration of exposure of poisoning. 
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As like BuChE the RBC-AChE is also low in conditions other than 
OPC poisoning they are, 
1. Carbamate poisoning 
2. Pernicious poisoning 
3. Therapy with anti-malarial or anti-depressants 
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Collection of blood samples for RBC-AChE must not be collected 
with fluoride containing test tubes as it may permanently disable the 
enzyme. The sample is ideally collected in anti-coagulated test tube like 
EDTA test tube. But this problem is not there with BuChE as it is not 
affected by any chelators or anti-coagulants.  
The OPCs and oxime can still exert their effect hence immediate 
dilution with saline or water in the ratio of 1:20 or 1:100 at bedside and 
cooled to 4ºC before rapidly freezing the test tube. This allows less 
variation and allows more uniform results. And again this is not a 
problem with BuChE as there is no rapid reactions with this enzyme. 
PROTEIN ADDUCTS: 
Mass spectrophometers are used to identify the protein adducts 
formed by the OPC with albumin, AChE and BuChE.  
The OrganoTox test is a fast, point of care test capable of detecting 
clinically relevant OPC poisoning after low-level exposure to soman, 
sarin, tabun or VX chemical nerve agents52. 
ATROPINE CHALLENGE: 
 In a patient presenting with the syndrome of cholinergic excess but 
with no history suggestive OPC intake an atropine challenge can be useful 
to diagnose the case. Atropine at the dose of 1mg in adolescents and 
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adults and 0.05mg/kg in case of paediatric population must produce the 
features of anti-muscarinic activity particularly mydriasis, dry mucus 
membranes and tachycardia while the persistence of cholinergic 
syndrome after the atropine challenge strongly suggest the patient is 
poisoned with a cholinesterase inhibitor poisoning like OPC15 . Some 
patients with mild doses of OPC poisoning may completely respond to 
this dose of atropine hence the reversal of cholinergic features will not 
exclude the poisoning by OPCs. 
ELECTROMYOGRAM STUDIES: 
 Electromyogram findings show 
 Spontaneous repetitive potential or fasciculation 
following the single-nerve stimulation. 
This is due to persistence of Ach in the nerve terminals or AChE 
inhibition at the motor end plate. This test is also useful in detecting 
rebound cholinergic crisis that will occur due to continued absorption or 
re-distribution from the fat stores. 
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DIFFERENTIAL DIAGNOSIS: 
The three important differential diagnosis of OPc poisonings are 
1. Insecticides and non-insecticides in which includes 
medicinal AChEs like neostigmine, echothiophate and 
pyridostigmine [cholinergic crisis in myasthenic patients 
treated with these agents] 
2. Second group includes the cholinomimetics they produce 
cholinergic syndrome without AChE or BuChE inhibition 
and essentially have normal AChE and BuChE levels 
3. The third group is nicotinic alkaloids they produce skeletal 
muscle, autonomic and CNS toxicities similar to OPCs 
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MANAGEMENT OF OPC POISONING 
GENERAL MANAGEMENT: 
1. The main cause of death in the OPC poisoned patients is the 
respiratory failure and resultant hypoxemia. This is due to 
the effect of increased Ach in the muscarinic receptors in the 
heart and pulmonary systems and producing increased 
tracheo-bronchial secretions, bronchospasm and brady 
cardia.  
2. The nicotinic effects in the CNS and peripheral nervous 
system causes loss of central respiratory drive and muscular 
weakness due to NMJ dysfunction similar to depolarizing 
muscle blockade. Which ultimately leads to respiratory 
failure, hypoxia and death. 
3. The initial treatment hence in case of OPC poisoning is 
assessment of airway, breathing and circulation and 
reversing the muscarinic effects.  
4. Seizures if it is not caused by hypoxia should be treated with 
adequate doses of benzodiazepines. 
5. Early tracheal intubation in patients who have excessive 
secretions and who are comatose with respiratory paralysis 
and cannot handle their secretions. 
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6. If a neuro muscular paralysis is needed for positive pressure 
ventilation only an agent which is not metabolised by the 
cholinesterase is used, because the scoline and mivacurium 
are metabolised by BuChE whose levels are very low in OPC 
poisoning. so the  duration of effect of these drugs may be 
prolonged for hours53,54. 
ANTI-MUSCARINIC THERAPY: 
 Atropine an anticholinergic drug competitive antagonist of 
acetylcholine at muscarinic receptor and it immediately reverses the 
muscarinic actions like 
1. Miosis 
2. Bradycardia 
3. Bronchospasm 
4. Vomiting, diarrhoea 
5. Urinary incontinence and diaphoresis 
Dose: 
1. For adults and adolescents i.v. dose should begin with 1-3mg 
depending upon the degree of symptoms 
2. For children the initial starting dose is 0.05mg/kg with a 
minimum dose of 0.1mg 
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3. Atropine dose must be repeated every 2-20 minutes in the 
range of 1-5mg until the ‘atropinisation’ occurs or dose can 
be doubled every five minutes until getting the desired 
response. 
Signs of ‘atropinisation’: 
1. Dry skin and mucus membranes 
2. Tachycardia 
3. Decreased or absent bowel movements 
4. No bronchospasm 
5. Reduced secretions 
6. Mydriasis 
As the patient usually die from cardiovascular and respiratory 
compromise so it is the heart rate, blood pressure, bronchorrhea and 
bronchospasm that is taken as signs of atropinisation not the mydriasis 
and dry skin. The vital target of atropinisation must be 
1. Heart rate > 80 BPM 
2. Systolic blood pressure> 90mmHg 
3. No bronchorrhea and no bronchospasm 
Maintenance dosing: 
 Once the signs of atropinisation is achieved the atropine must be 
given in i.v. infusion.  
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 The dose must be 10-20% of the initial loading dose but not 
exceeding the dose of 2mg/hr 
 Regular periodic monitoring is necessary and further boluses or 
halving the dose is maintained to prevent the over or under 
atropinisation.  
 Children need 0.025mg/kg/hr infusion.  
 The atropine infusion is mainly needed for those who consume 
highly fat soluble OPCs as they redistribute for long time. Case 
reports shows that the atropine requirement may be as long as 32 
days55. 
 Signs of over-atropinisation: 
1. Absent bowel sounds 
2. Marked tachycardia(>120 BPM) 
3. Mydriasis 
4. Urinary retention 
The complication of atropinisation is hyperthermia, agitation and 
confusion. The tachycardia per se is not an absolute contraindication as it 
may be due to aspiration pneumonia or hypovolemia. Isolated pulmonary 
manifestations may respond to nebulised atropine or ipratropium bromide 
however their efficacy is validated in trials. 
 Larger dose of atropine may be required to reverse the 
bronchospasm, bronchorrhea and bradycardia. Slightly poisoned patients 
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can do that well with 1-2 mg of atropine but severely poisoned patients 
may need up to 40mg. case reports shows that some patients needed 
1000mg within 24 hours with adequate dose of pralidoxime but without 
showing any anti-muscarinic effects56. And a total dose [over the full 
course of treatment] of as high as 11000mg is also reported. 
  Whether the higher dose is better than modest dose is not well 
studied but one study shows better results with infusion of 1mg/hr after 
the initial loading dose for adequate control of muscarinic effects57. 
 Atropine does not reverse the nicotinic effects of ACh excess. And 
patient must be closely monitored for impending respiratory failure 
resulting from peripheral NMJ dysfunction. Patient must be monitored for 
proximal muscle weakness especially of the neck muscle and the tidal 
volumes must be measured at least every 6 hours as an impending signs 
of respiratory failure and prompt administration of positive pressure 
ventilation. 
 Atropine when given in OPC poisoning the CNS manifestations of 
atropinisation will be evident but the muscarinic effects like bradycardia, 
bronchospasm and brocnchorrhea will be present. Under these situations 
the glycopyrrolate which is the quaternary ammonium compound and 
impermeable to the blood brain barrier is used. One study compared the 
atropine and glycopyrrolate in OPC poisoned patients in IMCU settings 
and found very small difference in effects between two regimens57. 
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 Intravenous glycopyrrolate  for adults is 1-2mg repeated as needed 
and the paediatric dose is 0.025mg/kg. Like atropine much higher doses 
of the drug is needed to control the muscarinic effects. 
 Scopolamine can also be used but it will cause much CNS effects. 
If the supplies of atropine is exhausted atropine ophthalmic preparation 
and other anti-cholinergic drugs like di-phenhydramine can also be used. 
OXIMES: 
 Although the phosphorylated AChE is regenerated spontaneously 
but the process is very slow and this process is catalysed by the presence 
of an oxime (2-PAM) or obidoxime. Thus decreasing the ACh levels at 
neuronal level and improvement in nicotinic and muscarinic symptoms. 
The RBC-AChE levels rises promptly following the treatment with 
oximes that parallels the rise in the neuronal AChE. 
The currently available Oximes is  
1. Monopyridinium Oximes 
a. Pralidoxime(2-PAM) 
2. Bispyridinium Oximes 
a. Obidoxime(toxogonin) 
b. Trimedoxime(TMB-4) 
c. Asoxime(HI-6) 
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Pralidoxime 
2-PAM 
 
 
 
 
Obidoxime 
Toxogonin, LuH-6 
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Trimedoxime 
TMB-4 
 
 
 
 
Asoxime 
HI-6 
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The aging rate of OPC poisoned enzyme vary with OPCs 
consumed. It’s early for dimethoxy compounds and relatively late for 
diethoxy compounds so the oxime therapy must be instituted within hours 
of OPC consumption and as early as possible. 
  The oxime therapy is particularly effective even if given late in 
case of fat soluble OPCs. As this compounds redistribute from the fat 
stores and cause new enzyme inhibition. Many case reports have 
validated this hypothesis by dramatically improving the weakness, 
reversing the paralysis and the cholinergic symptoms.
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
 
Diagram showing the mechanism of action of Oximes and regeneration of the free acetylcholinesterase
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Dosing of pralidoxime: 
  The recent clinical trial in our country showed that very high 
doses of 2-PAM reduces the length of ventilation and death in 
moderately poisoned patients58. 
 A loading dose of 2gram pralidoxime, in 100ml of 0.9%NaCl 
over 30 minutes followed by 8-10mg/kg/hr of pralidoxime 
chloride (upto 650mg of pralidoxime chloride or 1gram of 
pralidoxime iodide). 
Duration of treatment with Oximes: 
 It is recommended to continue the Oxime therapy until no 
atropine requirement for 12-24 hours. 
Other guidelines are, 
1. Measuring the serum or urinary concentration of the OP 
compound. 
2. Measuring serial determinations of plasma cholinesterase 
(increasing concentrations suggests the elimination of the OP 
compound). 
3. Incubating the patient’s serum with an exogenous source of 
AChE or butyrylcholinesterase to look for inhibition. 
4. Incubating the patient’s inhibited red blood cell cholinesterase 
with a high concentration of oxime in vitro, checking for 
reactivation.
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In all cases, patients should be observed for recrudescent toxicity 
after termination of pralidoxime. If symptoms return, therapy should 
be continued for at least 24 hours
Adverse effects: 
At therapeutic doses the side effects are minimal in humans 
1. Transient dizziness 
2. Blurred vision 
3. Elevation of diastolic BP which can be reversed with i.v. 
phentolamine 
4. Tachycardia 
5. Diplopia 
6. Elevated liver enzymes 
7. Rapid infusions cause sudden cardiac arrest due to laryngospasm 
and muscle rigidity 
8. Pralidoxime is pregnancy category C drug and it is used clinically 
to protect mother and foetus. 
BENZODIAZEPINES: 
In animal models it is suggested that OPCs inhibit the GABA 
transmission in synaptosomal preparations. Diazepam being an 
allosteric activator of GABA receptors is used along with atropine in 
OPC poisoning for neuro protection59. Diazepam also decreases the 
morphologic changes caused by OPC related seizures60. 
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The dose of diazepam as per WHO is 5-10mg if there is no 
seizures and 10-20mg i.v. bolus if the seizure is present. And it can be 
continued when needed. 
GACYCLIDINE
59
: 
 It is an anti-glutamatergic drug that inhibit seizures caused by 
nereve gas posonings like soman. It is also useful in conjunction with 
atropine, pralidoxime and diazepam. 
DECONTAMINATION IN OPC POISONING: 
1. Cutaneous absorption of OPCs and necessitates removal of all 
clothing as soon as possible.  
2. Medical personnel should avoid self-contamination by wearing 
neoprene or nitrile gloves. Double gloving with standard vinyl 
gloves may be protective.  
3. Skin should be triple washed with water, soap, and water, and 
rinsed again with water. Although alcohol-based soaps are 
sometimes recommended to dissolve hydrocarbons, these 
products can be difficult to find, and expeditious skin cleansing 
should be the primary goal.  
4. Cutaneous absorption can also result from contact with OPCs and 
compounds in vomitus and diarrhoea if the initial exposure was 
by ingestion.  
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5. Oily insecticides may be difficult to remove from thick or long 
hair, even with repeated shampooing, hence shaving scalp hair 
may be necessary.  
6. Exposed leather clothing or products should be discarded because 
decontamination is very difficult once impregnation has occurred. 
7. In some military institutions the cholinesterase impregnated 
sponge is found to be effective in cutaneous OPCs  
8. Although the Activated charcoal is useful in some studies a recent 
study shows that activated charcoal in multiple doses offer no 
benefit and hence once the risk of aspiration is ruled out the AC 
in a dose of 1gram/kg as a single dose is recommended61. 
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SCORING SYSTEM USED IN OPC POISONING 
Most of the OPC poisoned patients are managed in ICU settings. 
And the new advanced treatment modalities have resulted in increased 
survival in these patients. Such measures are also prolong the in 
hospital stay and increases the hospital expenses. So there is need of a 
scoring system for prognostication of these patients and also for 
avoiding expensive procedures and treatments. 
Scoring systems used OPC poisoning:62,63,64,65,66 
1. Poison severity score 
2. Glasgow coma scale 
3. APACHE II score 
4. Sequential organ failure assessment score [SOFA] 
5. Simplified acute physiology score II [SAPS] 
6. Modified APACHE II score [MAS] 
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APACHE II SCORE 
The APACHE II score is severity of disease classification system 
originally developed from the prototype APACHE score. 
It consists of 4 components, 
1. Acute physiology score 
2. Age 
3. Glasgow coma scale 
4. Chronic health status of that patient 
The APACHE II score is originally developed from the prototype 
scoring system APACHE score, the acute physiology score or the APS 
is derived from the abnormal twelve physiological variable. 12 
variables are chosen in the hypothesis that detecting abnormalities in 
multiple physiological variables helps us to quantify the magnitude of 
the severity of acute disease process. 
APACHE II score is objective type scoring system. The APS is 
calculated from the worst values obtained during the first 24 hours of 
ICU admission. The 24 hour time window is necessary to allow us to 
measure all the needed variables to calculate the APS. 
Each variable is given the weightage of 0-4. The total score 
obtained will be in the range of 0-71.  
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The acute physiology score [APS] consisting of twelve physiologic variable and each given the range 0-4. 


 
Eye opening Verbal [Non intubated] Verbal[intubated] Motor activity 
4 – spontaneous 5 – oriented and talks 5 – seems able to talk 6 – verbal commands 
3 – verbal stimuli 4 – disoriented and talks 3 – questionable ability to 
talk 
5 – localizes pain 
2 – painful stimuli 3 – inappropriate words 1 – generally unresponsive 4 – withdraws to pain 
1 – no response 2 – incomprehensible sounds  3 – decorticate posture 
 1 – no response  2 – decerebrate posture 
   1 – no response 
 
Glasgow coma scale: the GCS component of APACHE II score is calculated by subtracting the Observed GCS from 
15[ eg: if the GCS of that patient is 12 then (15-12=3)] 
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The age and chronic health score, if the patient has chronic health history and the patient is admitted any reason other 
than surgery will be given 5 points 

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CHRONIC HEALTH HISTORY: 
No. Chronic health status 
1 Biopsy proven cirrhosis and documented portal 
hypertension; past gastrointestinal bleeding attributed to 
portal hypertension; prior hepatic encephalopathy; prior 
hepatic failure 
2 NYHA class IV angina( at rest or minimal self-care 
activities) 
3 Chronic restrictive or obstructive or vascular lung diseases 
resulting in severe exercise limitation; documented 
hypoxemia or hypercapnia; secondary polycythemia; severe 
pulmonary hypertension(>40mmHg); ventilator dependence 
4 Chronic renal failure needing haemodialysis 
5 Immunosuppression from chemotherapy radiation therapy, 
long term or recent high dose steroids, 
immunodeficiency(e.g.: leukaemia, lymphoma, AIDS) 
 
 




MATERIALS AND METHODS 
 
SELECTION OF PATIENTS: 
 Patients admitted to toxicology unit of madras medical college and 
Rajiv Gandhi government general hospital with confirmed history of 
oraganophosphorous poisoning [OPC} are included in the study. On 
admission 10 cc of blood is withdrawn from the patient after obtaining 
informed consent either from the patient or the relatives. The sample is 
tested for complete blood count, renal function tests, liver function tests, 
arterial blood gases and serum electrolytes. As this study is both 
prospective and retrospective the lab parameters and clinical parameters 
of patients previously admitted are obtained from medical records 
department, Rajiv Gandhi government general hospital. 
STUDY CENTRE:  
 Institute of internal medicine, IMCU & Toxicology, Madras 
Medical College and Rajiv Gandhi Government General Hospital, park 
town, Chennai-600003. 
DURATION OF THE STUDY: 
 3 months 
STUDY DESIGN: 
 Prospective and Retrospective observational study 

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SAMPLE SIZE: 
 75 PATIENTS 
DATA COLLECTION AND METHODS: 
 Patients are subjected to history questioning, clinical examinations 
and blood sampling. Retrospective samples are obtained from case sheet 
records at medical records department. 
PROCEDURE / INVESTIGATION DETAILS: 
1. Complete blood count   
2. Renal function test – urea, creatinine 
3. Serum sodium 
4. Serum potassium 
5. Arterial blood gas assessment for pH, paO2 
6. Vital parameters including rectal temperature, oxygen saturation, 
respiratory rate, pulse rate and blood pressure. 
INCLUSION CRITERIA: 
1. Age: above 18 years. 
2. Sex-both genders. 
3. Patients presenting with confirmed consumption of 
organophosphorous compounds. 
4. Patients willing to give written informed consent. 
 




EXCLUSION CRITERIA: 
1. Age less than 18 years. 
2. Patients who consumed substances other than organophosphates and 
mixed compound poisonings. 
STATISTICAL METHODS: 
 The statistical analysis is done using SPSS software. ‘p’ value 
obtained is analysed using the SPSS software. 
SPONSORSHIP: 
 NO 
CONFLICT OF INTEREST: 
 NONE 
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OBSERVATION AND RESULTS 
 
Flow chart depicting the process of the study 
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SEX WISE DISTRIBUTION 
Total number of cases: 75 
SL. NO MALE FEMALE TOTAL 
NUMBER 59 16 75 
PERCENTAGE 78.6 21.4 100% 
 
 
 
 
  
59, 79%
16, 21%
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SURVIVAL AND MORTALITY: 
 
Total number of cases 75 
survivors 61 
Non survivors 14 
percentage of survivors 81.33 
Percentage of non survivors 18.66 
 
Bar diagram comparing the survivors and non survivors and 
their percentage 
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SEX WISE MORTALITY 
Table: showing mortality among males and females 
 MALE FEMALE 
TOTAL 59 16 
ALIVE 46 15 
DEAD 13 1 
PERCENTAGE LIVE 77.96% 93.75% 
PERCENT DEAD 22.03% 6.25% 
 
 
THE MEAN OF AGE DEATH IN MALES IS  : 46 
THE MEAN AGE OF DEATH IN FEMALES IS  : 66 
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 Bar diagram comparing the age wise and sex wise survived and dead patients 
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Table : showing patient numbers according to the age group 
 
 
In our study 64% of the patients belong to the group of less than 45 
years of age 
 
 
 
 
 
 
Age group Number of patients in 
each 
survived dead Mortality 
percentage 
45< 48 43 5 10.41% 
45-54 14 11 3 21.42% 
55-64 8 5 3 37.5% 
65-74 3 0 3 100% 
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AGE: 
 
Variable Survivors Non-survivors p value 
Age 37.18 ± 12.92 47.28 ± 15.3 0.001 
± Standard deviation, the p value is calculated using the t-test for two 
independent samples. 
In our study the difference in age among the survivors and non 
survivors is significant p value 0.001(<0.05).
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Table: showing the number of patients who consumed each OPCs 
OPC Number of patients 
1. Methyl parathion 11 
2. Phorate 2 
3. Monocrotophos 15 
4. Trizophos 5 
5. Dichlorvas 5 
6. quinalphos 2 
7. chlorpyriphos 8 
8. dimethoate 7 
9. fenthion 2 
10. prophenophos 8 
11. phenthoate 7 
12. acephate 1 
13. ethion 1 
14. malathion 1 
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Table: Patients who consumed as per WHO class 
Class of poison Number of patients 
Class Ia 13 
Class Ib 24 
Class II 37 
Class III 1 
 
As per WHO class about 50% of the poisonings belong to classs II 
group, 33% belong to class Ib group. And only one patient in class III 
group. 
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Bar diagram showing the number of patients consumed poison as per WHO class 
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Table: showing number of patients classified with time of presentation 
 
Time elapsed Number of cases 
Less than 6hours 56 
6-12hours 19 
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Bar diagram showing number of patients classified with time of 
presentation 
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Bar diagram comparing the significance of time elapsed till admission and 
mortality 
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RECTAL TEMPERATURE: 
 
Variable Survivors Non survivors P value 
Rectal 
temperature 
37.53±0.76 36.47±0.72 <0.0001 
± Standard deviation, the p value is calculated using the t-test for two 
independent samples. 
In our study the difference in rectal temperature among survivors 
and non survivors is significant with p value <0.0001. 
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Bar diagram showing the comparison between the average rectal 
temperature (ºC) among the survivors and non survivors 
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GLASGOW COMA SCALE: 
 
variable survivors Non survivors p value 
GCS 12(8-15) ± 1.576 8(6-12) ± 1.557 <0.0001 
 ± is standard deviation, the values in parantheses are the range of 
score obtained in each group. The p value is calculated using the t-test for 
two independent samples. 
 In our study the difference in Glasgow coma scale among survivors 
and non survivors is significant with p value <0.0001. 
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Bar char representing the comparison of Glasgow coma scale among the 
survived and dead. 
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MEAN ARTERIAL PRESSURE: 
 
Variable Survivors Non survivors P value 
MAP 87.57±15.76 82±26.70 0.30 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples. 
 In our study the difference in mean arterial pressure among the 
survivors and non survivors is not significant p value 0.30(>0.05). 
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Bar diagram showing the average mean arterial pressure (mm Hg) among 
the survivors and non survivors 
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HEART RATE: 
 
Variable Survivors Non survivors P value 
Heart rate 67.91±13.62 62.71±22.30 0.262 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
In our study the difference in heart rate among the survivors and 
non survivors is not significant p value 0.262(>0.05). 
Though the initial rate is normal in OPC poisoned patients. They 
develop bradycardia at some point of time during the first 24 hours of 
hospital admission. As our patients are not maintained in atropine 
infusion and atropine is given as per the atropine requirement chart. 
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Bar diagram showing the comparison of average heart rate (per minute) 
among the survivors and non survivors 
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RESPIRATORY RATE: 
 
Variable Survivors Non survivors P value 
Respiratory rate 18.88±4.15 23.50±7.37 0.002 
 ± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in respiratory rate among the survivors 
and non survivors is significant p value 0.002(<0.05). 
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Bar diagram showing the comparison of average respiratory rate (per 
minute) among the survivors and non survivors 
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pH: 
 
Variable Survivors Non survivors P value 
pH 7.381±0.05 7.25±0.04 <0.0001 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in pH among the survivors and non 
survivors is significant p value 0.0001(<0.05). 
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Bar diagram showing the comparison of average respiratory rate among 
the survivors and non survivors 
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OXYGENATION: 
 
Variable Survivors Non survivors P value 
Oxygenation 111.88±28.66 60.57±26.78 <0.0001 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in oxygenation among the survivors and 
non survivors is significant p value 0.0001(<0.05). 
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Bar diagram showing the comparison of average oxygenation (mm Hg) 
among the survivors and non survivors 
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SERUM UREA: 
 
Variable Survivors Non survivors P value 
Serum urea 33.75±7.99 53.35±18.40 <0.0001 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in serum urea among the survivors and 
non survivors is significant p value 0.0001(<0.05). 
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Bar diagram showing the comparison of average serum urea (mg/dl) 
among the survivors and non survivors 
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SERUM CREATININE: 
 
Variable Survivors Non survivors P value 
Serum creatinine 0.95±0.19 1.50±0.59 <0.0001 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in serum creatinine among the survivors 
and non survivors is significant p value 0.0001(<0.05). 
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Bar diagram showing the comparison of average serum creatinine (mg/dl) 
among the survivors and non survivors 
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SERUM SODIUM:  
 
Variable Survivors Non survivors P value 
Serum sodium 136.50±5.91 137.42±4.41 0.586 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in serum sodium among the survivors 
and non survivors is not significant p value 0.586(>0.05). 
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Bar diagram showing the comparison of average serum sodium (mEq/L) 
among the survivors and non survivors 
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SERUM POTASSIUM:  
 
Variable Survivors Non survivors P value 
Serum 
potassium 
3.73±0.53 4.23±0.79 0.005 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in serum potassium among the survivors 
and non survivors is significant p value 0.005(<0.05). 
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Bar diagram showing the comparison of average serum potassium 
(mEq/L) among the survivors and non survivors 
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HAEMATOCRIT: 
 
Variable Survivors Non survivors P value 
Haematocrit 38.08±5.01 38.07±4.25 0.994 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
In our study the difference in haematocrit among the survivors and 
non survivors is not significant p value 0.994(>0.05). 
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Bar diagram to compare the haematocrit among the survivors and non 
survivors 
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WBC COUNT: 
 
Variable Survivor Non survivor P value 
WBC count 6667.21±2171.23 9228.57±2893.42 1.993 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
In our study the difference in WBC count among the survivors and 
non survivors is not significant p value 1.993(>0.05). 
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Bar diagram to compare the WBC count among the survivors and non 
survivors 
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APACHE II SCORE: 
 
Variable Survivors Non survivors p value 
APACHE II 5.70 ± 3.01 19.57 ± 3.93 <0.0001 
± is standard deviation, the p value is calculated using the t-test for two 
independent samples 
 In our study the difference in APACHE II score among the 
survivors and non survivors is significant p value 0.0001(<0.05). 
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Bar diagram to compare the APACHE II score among the survivors and 
non survivors 
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DISCUSSION 
This study is a prospective and retrospective observational study 
and was done in toxicology unit of madras medical college and Rajiv 
Gandhi government general hospital. 75 patients with confirmed history 
or documented OPC poisoning is taken for study. Most of the severely 
poisoned patients are referred cases from nearby government hospitals in 
the view of respiratory failure or impending failure. Informed consent is 
obtained from the prospective samples. The necessary parameters from 
the retrospective samples obtained from the case records of medical 
records department of Rajiv Gandhi government general hospital. 
The organophosphate compounds are the most common mode of 
suicidal poisonings in India. The most common mode of death in OPC 
poisoning is due to respiratory failure. Most of the severely poisoned 
patients need to intubation and mechanical ventilation and must be closely 
monitored in ICU settings. Multiple organ system involvement is 
common in OPC poisoning as this muscarinic and nicotinic receptors are 
virtually present in almost all organ systems.  
 The APACHE II score is objective type scoring system. The score 
is calculated from the worst values obtained during the first 24 hours of 
ICU admission 
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


APACHE II score = APS+ GCS +Age+ chronic health status 
  
Many studies62,63,64,65 shown the discriminative value of APACHE 
II score in the assessment of outcomes of OPC poisoning. The APACHE 
II score is useful especially in patients with multiple organ dysfunction 
due to acute insult like OPC poisoning. 
  The minimum APACHE II score obtained in our study is 0 and 
the maximum score obtained in our study is 27. The mean APACHE II 
score in survivors is 5.70 with standard deviation of 3.01 and in non 
survivors is 19.57 with standard deviation of 3.93. No one patient 
survived with APACHE II score of more than 15. 
The difference in APACHE II score is statistically significant 
among the survivors and non survivors. All the statistical analysis are 
done using the t-test for two independent samples 
Other parameters which are shown to be statistically significant 
[p<0.05] in our study are age, Glasgow coma scale, rectal temperature, 
respiratory rate, pH, oxygenation, serum urea, serum creatinine and serum 
potassium. Though insignificant the WBC count is increased in non 
survivors group may be due to aspiration pneumonia. 
Parameters thet are responsible for increased APACHE II score in 
non survivors group is age, GCS, oxygenation and pH. 

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The chronic health history is present in only two of our patients. 
Both have immunodeficiency one due to retroviral disease and the other 
had an active malignancy and was on chemotherapy and both patients 
expired. 
APACHE II score predicts the severity of acute physiological 
dysfunction due to multi organ involvement in OPC poisoning and can be 
recommended as a useful scoring system in OPC poisonings in ICU 
settings 
Limitations of the study: 
1. Further studies with large sample size and multicentre studies 
with different population are needed to conform the use of 
APACHE II score in predicting the severity and clinical 
outcomes of organophosphorous poisoning. 
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CONCLUSION 
 
 APACHE II score is an objective scoring system and 
it is useful in the predicting the clinical outcome in the 
Acute Organophosphorous poisonings in the Intensive 
care settings. 
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ABBREVATIONS 
 
OPC  : Organo phosphorous compound 
WHO  : world health organization 
PAM  : pralidoxime 
APACHE : acute physiology and chronic health evaluation 
GCS  :  glassgow coma scale 
AChE : Acetylcholinesterase 
ACh  : Acetylcholine 
BuChE : Butyrylcholinesterase 
NMJ  :  neuro muscular junction 
RBC-AChE : red blood cell Acetylcholinesterase 
Hb  : Haemoglobin 
HCT  :  haematocrit 
WBC  :  white blood cell 
Sr.  : Serum 
 
 
 
 
 
 
STUDY PROFORMA SHEET 
 
 
1. Name :  
2. Patient ID No: 
3. Age/Sex :       
4. Contact No: 
5. Address: 
6. Date of admission with time:                                                  
7. Date of discharge: 
8. Occupation: 
9. Substance consumed: 
10. Time of consumption: 
11. Place of consumption: 
12. Time elapsed since consumption to admission: 
13. WHO hazard scale of the consumed Substance? 
14. Chronic health history(any of the following): 
I. Liver: Cirrhosis with portal hypertension or encephalopathy 
II. CVS: class IV angina 
III. Pulmonary: chronic hypoxia, hypercapnea, polycythemia, 
IV. Kidney: chronic peritoneal or haemodialysis 
V. Immune status: immunocompromised host 
15. Glasgow coma scale:  
VITAL PARAMETERS: 
o BLOOD PRESSURE (SYS/DIA): 
o PULSE RATE: 
o RESPIRATORY RATE: 
o Spo2: 
o RECTAL TEMPERATURE: 
INVESTIGATIONS: 
1. COMPLETE BLOOD COUNT 
2. RENAL FUNCTION TESTS 
a. UREA(mg/dl): 
b. Creatinine (mg/dl): 
3. SERUM ELECTROLYTES 
a. Serum sodium (mEq/L): 
b. Serum potassium (mEq/L): 
4. Arterial blood gases: 
OUTCOME OF THE PATIENT ( tick in appropriate boxes): 
1. survived 
2. Not survived 
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INFORMATION SHEET 
 
We are conducting a study on “EVALUATING THE USE OF 
APACHE II SCORE IN PREDICTING THE SEVERITY AND 
CLINICAL OUTCOMES OF ORGANOPHOSPHOROUS 
POISONING” among patients attending Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be 
valuable to us. 
The purpose of this study is to assess the efficacy of the APCHE 
II score in guiding prognosis of organophosphorous poisoning. 
We are selecting certain cases and if you are found eligible, after 
filling up the questionnaire, 10 ml blood will be collected from you. 
You will also undergo ECG, Biochemistry, and arterial blood gas 
measurement. These tests and special studies do not affect your final 
report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information 
will be shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are 
otherwise entitled. 
The results of the special study may be intimated to you at the 
end of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
 
Signature of the investigator    Signature of the  
Participant/impartial witness 
 
Date:        Date:
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PATIENT CONSENT FORM 
 
Study Title : Evaluating the use of APACHE II score in predicting 
the severity and clinical outcomes of 
organophosphorous poisoning 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification Number :  
Patient may check () these boxes 
The details of the study have been provided to me in writing and explained to me in 
my own language ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that investigator of the clinical study, others working on the 
investigators’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being 
or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological and biochemical tests. ❏ 
 
 
Signature/thumb impression of Patient/impartial 
witness 
Name:  
Address:
Signature of Investigator 
Study Investigator’s Name: 
Dr. VIVEKANANDAN A 
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1 85113 37 1 M 12 1 3 2 38.2 15 70 56 28 7.14 230.8 36 1.4 146 2.2 38 11300 1 9 
2 82778 48 2 M 1 1 1 2 37.4 15 80 124 25 7.39 75 49 1.3 143 3.2 42 14200 1 6 
3 85363 24 1 M 9 1 3 2 37.9 7 123 102 29 7.24 147 52 1.7 135 3.5 46 15800 2 19 
4 82239 58 3 M 1 1 1 2 37 9 68 124 32 7.18 56 50 1.9 135 4.1 43 11200 2 27 
5 85202 41 1 M 4 2 2 2 38 15 83 100 18 7.38 154 23 0.8 139 4 46 9200 1 0 
6 84331 24 1 M 8 1 3 2 37.1 15 69 110 20 7.42 132 35 0.9 134 3.6 45 8400 1 2 
7 81570 48 2 F 9 1 3 2 38.3 15 106 80 14 7.36 118 24 0.8 134 3.1 38 6800 1 3 
8 81427 24 1 M 5 2 2 2 37.1 12 80 65 18 7.35 145 35 1 134 3.2 42 8400 1 6 
9 80241 50 2 M 8 1 3 2 37.8 11 105 54 22 7.37 110 41 1.1 139 3 38 6600 1 10 
10 79086 55 3 M 9 2 3 2 37.9 12 120 70 16 7.41 98 56 1.4 140 4.5 32 5800 1 8 
11 78701 55 3 M 12 2 3 2 37.4 13 118 54 19 7.46 101 61 1.6 142 4.5 40 9200 1 12 
12 77371 24 1 F 4 1 2 2 40.2 12 80 57 24 7.48 121 28 1.2 129 3.7 35 10500 1 10 
13 77327 23 1 M 1 2 1 2 38.7 11 83 64 28 7.31 118 18 1 138 3.5 46 6300 1 11 
14 75744 20 1 M 4 2 2 2 39 10 93 78 20 7.38 159 29 0.9 136 2.9 44 7100 1 10 
15 72688 24 1 F 15 1 3 2 39.1 15 93 50 21 7.39 117 31 0.8 145 3 30 7900 1 6 
16 72736 24 1 M 12 1 3 2 37.4 13 83 60 20 7.42 101 34 0.8 134 3.9 41 7300 1 4 
17 72688 55 3 M 4 2 2 1 36.2 8 60 49 18 7.29 61 54 1.4 142 4.9 43 11200 2 22 
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18 72226 18 1 F 1 2 1 2 37.2 12 70 50 28 7.33 89 36 1 136 4.1 34 5400 1 6 
19 71900 53 2 M 12 1 3 2 39.2 11 128 57 17 7.34 126 32 0.9 143 4.4 39 4600 1 13 
20 71047 27 1 F 4 1 2 2 37 12 83 64 24 7.4 156 29 0.8 140 4 43 4900 1 5 
21 70644 55 3 M 9 1 3 2 38 10 100 59 24 7.42 160 38 1.2 144 4.9 37 4700 1 7 
22 69946 65 4 M 4 1 2 2 36 7 103 49 11 7.24 65 44 1.6 144 5.1 40 8900 2 18 
23 69921 18 1 M 11 1 3 2 37.4 13 83 74 16 7.34 121 28 0.8 139 4.2 44 5600 1 2 
24 69743 35 1 F 12 1 3 2 37.1 12 80 59 18 7.3 70 40 1.1 141 4.6 32 7200 1 7 
25 67282 34 1 M 11 2 3 2 38 10 100 60 14 7.34 89 45 1.4 132 3.6 28 8100 1 9 
26 66421 26 1 M 4 1 2 2 37.2 11 90 54 16 7.35 90 40 1.1 137 3.5 45 7300 1 7 
27 65310 18 1 M 5 1 2 2 38.6 10 80 64 28 7.34 66 35 1 132 3.1 38 7700 1 10 
28 65100 20 1 M 1 1 1 2 38.4 11 90 78 16 7.36 178 28 0.9 137 3.6 39 4900 1 4 
29 64071 46 2 M 6 2 2 2 37.8 10 106 62 21 7.38 144 40 1.1 145 5 33 6700 1 7 
30 63018 26 1 M 1 1 1 2 36.7 7 63 56 29 7.3 54 45 1.2 141 4.7 39 7100 2 19 
31 59524 35 1 M 4 2 2 2 36.1 6 70 50 26 7.28 58 40 0.9 143 4.2 37 8900 2 18 
32 57685 22 1 M 4 1 2 2 37.1 11 80 64 20 7.34 129 41 1.1 142 4.6 39 15600 1 6 
33 56338 50 2 M 12 1 3 2 36.8 12 133 69 17 7.36 144 39 1.2 144 4.1 38 7300 1 5 
34 55044 19 1 F 8 1 3 2 37.4 12 70 71 22 7.37 138 27 0.8 138 3.9 28 5400 1 5 
35 58037 24 1 M 4 1 2 2 37.8 12 70 64 21 7.35 114 32 0.9 135 3.5 42 5900 1 5 
36 54548 45 2 M 8 1 3 2 37.7 11 70 62 18 7.38 98 42 1.1 129 3.6 38 5200 1 6 
37 54588 65 4 M 11 2 3 2 36.9 8 123 52 14 7.28 62 41 0.9 134 4.6 36 9400 2 15 
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38 54889 21 1 M 4 1 2 2 38.1 13 83 61 20 7.36 102 35 0.8 139 4 42 8400 1 4 
39 54555 47 2 M 8 1 3 2 37.6 14 96 74 18 7.38 124 32 0.9 140 3 39 6200 1 2 
40 54069 52 2 F 1 1 1 2 38.1 11 83 64 26 7.37 102 39 1 141 3.5 28 7300 1 8 
41 53705 32 1 M 6 2 2 2 37.2 13 80 70 18 7.38 110 32 0.9 129 3.2 36 6600 1 5 
42 52900 22 1 F 1 1 1 2 36.4 11 70 82 21 7.39 95 29 0.8 131 3.7 33 5600 1 4 
43 51603 38 1 M 6 2 2 2 36.8 13 80 68 22 7.35 84 35 0.7 139 3.8 40 7400 1 4 
44 51423 23 1 M 9 2 3 2 37 13 93 70 16 7.41 100 31 0.8 132 3.6 42 5400 1 2 
45 51402 44 1 M 13 1 3 2 37.2 15 83 78 14 7.43 138 30 0.7 129 3.7 44 5100 1 2 
46 51063 60 3 M 7 2 3 2 35.2 7 60 54 24 7.22 50 59 1.8 140 5.2 38 12600 2 25 
47 50713 30 1 M 5 1 2 2 36.8 15 83 82 14 7.42 98 34 1.1 134 3.1 43 4600 1 1 
48 50588 30 1 M 8 1 3 2 37.6 13 83 84 16 7.4 119 31 0.9 138 3.6 39 4900 1 2 
49 49425 27 1 F 4 1 2 2 37.4 13 70 61 19 7.35 94 37 0.8 136 3.9 30 7100 1 4 
50 48747 25 1 M 1 1 1 2 38.1 14 80 79 14 7.38 101 25 0.8 133 3.6 43 6200 1 1 
51 43665 38 1 M 11 1 3 2 37.2 13 106 68 17 7.34 123 40 1 128 3.1 36 5800 1 7 
52 48669 35 1 M 10 1 3 2 37.8 14 103 74 13 7.37 97 36 0.8 132 3.7 39 4700 1 1 
53 48599 26 1 M 11 1 3 2 36.9 13 83 78 17 7.39 88 33 0.7 137 3.4 44 5600 1 3 
54 48763 22 1 F 4 1 2 2 36.3 12 80 82 24 7.42 98 31 0.9 138 3.6 33 4800 1 3 
55 48323 55 3 M 3 1 1 2 36.1 10 73 52 23 7.4 75 42 1.1 141 3.8 35 6900 1 8 
56 45008 44 1 M 12 2 3 2 37.2 13 83 78 19 7.4 98 36 0.9 134 3.2 39 7200 1 3 
57 45745 45 2 M 5 2 2 2 36.1 6 70 50 29 7.24 62 59 1.5 130 3.3 36 9000 2 17 
58 45350 34 1 M 9 1 3 2 35.4 7 63 66 25 7.21 50 110 3.2 138 5.6 39 7800 2 24 
59 45000 48 2 M 8 1 3 2 36.8 8 126 58 21 7.3 65 40 1 134 3.6 34 5600 2 12 
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60 44964 66 4 F 4 1 3 1 36.2 6 63 55 36 7.35 30 35 1 137 3.8 30 7800 2 19 
61 43675 52 2 M 11 1 3 2 36.8 13 110 56 16 7.41 100 30 0.9 129 3.5 36 4600 1 10 
62 43244 53 2 M 6 1 2 2 37.2 7 100 51 21 7.21 40 54 1.4 131 3.7 33 4300 2 20 
63 43204 55 3 M 7 1 3 2 38 14 103 54 14 7.36 92 28 1 137 4.1 35 5700 1 7 
64 42458 58 3 M 6 1 2 2 38.2 12 123 62 18 7.4 117 27 0.9 134 4.6 38 5900 1 10 
65 41693 19 1 M 10 1 3 2 37.1 13 83 63 13 7.33 92 18 0.9 135 4.5 42 7000 1 4 
66 41234 47 2 M 11 1 3 2 37.4 13 80 65 19 7.41 104 34 0.8 133 4.2 39 3600 1 6 
67 40193 18 1 M 1 1 1 2 36.8 12 80 69 21 7.45 90 39 0.9 134 4 44 4800 1 5 
68 40168 24 1 F 14 1 3 2 36.6 13 93 61 14 7.41 88 40 1 141 3.7 33 5500 1 4 
69 39593 45 2 M 11 1 3 2 37.1 14 93 50 12 7.49 113 23 0.7 145 3.8 38 4900 1 6 
70 39344 18 1 F 4 1 2 2 37 13 63 57 16 7.47 96 29 0.8 111 3.5 35 7200 1 9 
71 37690 22 1 M 8 2 3 2 38.2 13 73 60 18 7.44 80 25 0.7 130 4.1 44 5700 1 4 
72 36788 38 1 M 9 1 3 2 36.4 13 93 64 11 7.41 79 40 0.9 142 4 36 3700 1 5 
73 35894 28 1 M 1 1 1 2 36.9 12 56 62 14 7.24 48 64 1.6 140 3 39 9600 2 19 
74 35385 27 1 F 3 1 1 2 37 8 70 70 17 7.36 124 19 0.7 132 3.6 24 7500 1 9 
75 35008 44 1 M 5 1 2 2 37 11 70 74 19 7.38 112 27 0.8 146 3.5 40 5300 1 4 
 
KEY TO MASTER CHART 
 
AGE GROUP: 
<45  : 1 
45 – 54 : 2 
55 – 64 : 3 
>75  : 4  
 
SUBSTANCE CONSUMED: 
Methyl parathion : 1 
Phosphamidon : 2 
Phorate  : 3 
Monocrotophos : 4 
Triazophos  : 5 
Dichlorvas  : 6 
Quinalphos  : 7 
Chlorpyriphos : 8 
Dimethoate  : 9 
Fenthion  : 10 
Prophenophos : 11 
Phenthoate  : 12 
Acephate  : 13 
Ethion  : 14 
Malathion  : 15 
Temephos  : 16 
Tetra chlorinphos : 17 
 
 
 
WHO CLASS: 
Class Ia : 1 
Class Ib : 2 
Class II : 3 
Class III : 4 
 
TIME ELAPSED: 
<6hr   : 1 
6 – 12 hours  : 2 
13 – 24 hours : 3 
>24 hours  : 4 
 
CHRONIC HEALTH STATUS: 
Yes : 1 
No : 2 
 
OUTCOME: 
Survivor  :  1 
Non survivor : 2 
